Cargando…

Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I)

BACKGROUND: Treatment plans for squamous cell carcinoma of the head and neck (SCCHN) are individually decided in tumor board meetings but some treatment decision-steps lack objective prognostic estimates. Our purpose was to explore the potential of radiomics for SCCHN therapy-specific survival progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernatz, Simon, Böth, Ines, Ackermann, Jörg, Burck, Iris, Mahmoudi, Scherwin, Lenga, Lukas, Martin, Simon S., Scholtz, Jan-Erik, Koch, Vitali, Grünewald, Leon D., Koch, Ina, Stöver, Timo, Wild, Peter J., Winkelmann, Ria, Vogl, Thomas J., dos Santos, Daniel Pinto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236822/
https://www.ncbi.nlm.nih.gov/pubmed/37268876
http://dx.doi.org/10.1186/s12880-023-01034-1
_version_ 1785053026778611712
author Bernatz, Simon
Böth, Ines
Ackermann, Jörg
Burck, Iris
Mahmoudi, Scherwin
Lenga, Lukas
Martin, Simon S.
Scholtz, Jan-Erik
Koch, Vitali
Grünewald, Leon D.
Koch, Ina
Stöver, Timo
Wild, Peter J.
Winkelmann, Ria
Vogl, Thomas J.
dos Santos, Daniel Pinto
author_facet Bernatz, Simon
Böth, Ines
Ackermann, Jörg
Burck, Iris
Mahmoudi, Scherwin
Lenga, Lukas
Martin, Simon S.
Scholtz, Jan-Erik
Koch, Vitali
Grünewald, Leon D.
Koch, Ina
Stöver, Timo
Wild, Peter J.
Winkelmann, Ria
Vogl, Thomas J.
dos Santos, Daniel Pinto
author_sort Bernatz, Simon
collection PubMed
description BACKGROUND: Treatment plans for squamous cell carcinoma of the head and neck (SCCHN) are individually decided in tumor board meetings but some treatment decision-steps lack objective prognostic estimates. Our purpose was to explore the potential of radiomics for SCCHN therapy-specific survival prognostication and to increase the models’ interpretability by ranking the features based on their predictive importance. METHODS: We included 157 SCCHN patients (male, 119; female, 38; mean age, 64.39 ± 10.71 years) with baseline head and neck CT between 09/2014 and 08/2020 in this retrospective study. Patients were stratified according to their treatment. Using independent training and test datasets with cross-validation and 100 iterations, we identified, ranked and inter-correlated prognostic signatures using elastic net (EN) and random survival forest (RSF). We benchmarked the models against clinical parameters. Inter-reader variation was analyzed using intraclass-correlation coefficients (ICC). RESULTS: EN and RSF achieved top prognostication performances of AUC = 0.795 (95% CI 0.767–0.822) and AUC = 0.811 (95% CI 0.782–0.839). RSF prognostication slightly outperformed the EN for the complete (ΔAUC 0.035, p = 0.002) and radiochemotherapy (ΔAUC 0.092, p < 0.001) cohort. RSF was superior to most clinical benchmarking (p ≤ 0.006). The inter-reader correlation was moderate or high for all features classes (ICC ≥ 0.77 (± 0.19)). Shape features had the highest prognostic importance, followed by texture features. CONCLUSIONS: EN and RSF built on radiomics features may be used for survival prognostication. The prognostically leading features may vary between treatment subgroups. This warrants further validation to potentially aid clinical treatment decision making in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12880-023-01034-1.
format Online
Article
Text
id pubmed-10236822
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102368222023-06-03 Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I) Bernatz, Simon Böth, Ines Ackermann, Jörg Burck, Iris Mahmoudi, Scherwin Lenga, Lukas Martin, Simon S. Scholtz, Jan-Erik Koch, Vitali Grünewald, Leon D. Koch, Ina Stöver, Timo Wild, Peter J. Winkelmann, Ria Vogl, Thomas J. dos Santos, Daniel Pinto BMC Med Imaging Research BACKGROUND: Treatment plans for squamous cell carcinoma of the head and neck (SCCHN) are individually decided in tumor board meetings but some treatment decision-steps lack objective prognostic estimates. Our purpose was to explore the potential of radiomics for SCCHN therapy-specific survival prognostication and to increase the models’ interpretability by ranking the features based on their predictive importance. METHODS: We included 157 SCCHN patients (male, 119; female, 38; mean age, 64.39 ± 10.71 years) with baseline head and neck CT between 09/2014 and 08/2020 in this retrospective study. Patients were stratified according to their treatment. Using independent training and test datasets with cross-validation and 100 iterations, we identified, ranked and inter-correlated prognostic signatures using elastic net (EN) and random survival forest (RSF). We benchmarked the models against clinical parameters. Inter-reader variation was analyzed using intraclass-correlation coefficients (ICC). RESULTS: EN and RSF achieved top prognostication performances of AUC = 0.795 (95% CI 0.767–0.822) and AUC = 0.811 (95% CI 0.782–0.839). RSF prognostication slightly outperformed the EN for the complete (ΔAUC 0.035, p = 0.002) and radiochemotherapy (ΔAUC 0.092, p < 0.001) cohort. RSF was superior to most clinical benchmarking (p ≤ 0.006). The inter-reader correlation was moderate or high for all features classes (ICC ≥ 0.77 (± 0.19)). Shape features had the highest prognostic importance, followed by texture features. CONCLUSIONS: EN and RSF built on radiomics features may be used for survival prognostication. The prognostically leading features may vary between treatment subgroups. This warrants further validation to potentially aid clinical treatment decision making in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12880-023-01034-1. BioMed Central 2023-06-02 /pmc/articles/PMC10236822/ /pubmed/37268876 http://dx.doi.org/10.1186/s12880-023-01034-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bernatz, Simon
Böth, Ines
Ackermann, Jörg
Burck, Iris
Mahmoudi, Scherwin
Lenga, Lukas
Martin, Simon S.
Scholtz, Jan-Erik
Koch, Vitali
Grünewald, Leon D.
Koch, Ina
Stöver, Timo
Wild, Peter J.
Winkelmann, Ria
Vogl, Thomas J.
dos Santos, Daniel Pinto
Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I)
title Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I)
title_full Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I)
title_fullStr Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I)
title_full_unstemmed Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I)
title_short Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I)
title_sort radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part i)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236822/
https://www.ncbi.nlm.nih.gov/pubmed/37268876
http://dx.doi.org/10.1186/s12880-023-01034-1
work_keys_str_mv AT bernatzsimon radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT bothines radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT ackermannjorg radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT burckiris radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT mahmoudischerwin radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT lengalukas radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT martinsimons radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT scholtzjanerik radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT kochvitali radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT grunewaldleond radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT kochina radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT stovertimo radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT wildpeterj radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT winkelmannria radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT voglthomasj radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti
AT dossantosdanielpinto radiomicsfortherapyspecificheadandnecksquamouscellcarcinomasurvivalprognosticationparti